Hannah Berner’s Dysport Mishap Explained: Risks, Recovery, and Safe Jaw Botox Tips
By Robert Thorne
The biological reality of neurotoxin complications is that there is no reversing agent. Unlike hyaluronic acid dermal fillers, which dissolve within hours using hyaluronidase injections, neuromodulators must wear off naturally as the body sprouts new nerve terminals.
The table below outlines how neurotoxin variables impact masseter outcomes, diffusion risks, and recovery phases across modern clinical settings:
| Product & Parameter | Typical Masseter Dosing | Diffusion Profile | Mishap Recovery Window |
|---|---|---|---|
| Dysport (AbobotulinumtoxinA) | 60, 120 Units (Total Jaw) | Broader spread; fast onset (2, 4 days) | 10, 14 Weeks until motor return |
| Botox (OnabotulinumtoxinA) | 25, 50 Units (Total Jaw) | Tighter, localized field (5, 7 days onset) | 12, 16 Weeks until motor return |
| Xeomin (IncobotulinumtoxinA) | 25, 50 Units (Total Jaw) | Clean protein; moderate spread | 10, 14 Weeks until motor return |
| Daxxify (DaxibotulinumtoxinA) | 50, 100 Units (Total Jaw) | Peptide-stabilized; highly concentrated | 16, 24 Weeks until motor return |
For Berner, the physical timeline meant adjusting to weeks of altered speech mechanics and limited facial expression while performing on tour. While the jaw clenching stopped, the trade-off demanded months of patience.
Robert Thorne covers electric vehicle innovations, autonomous driving systems, global mobility trends, and automotive engineering developments.
